Treatment of Severe Alopecia Areata with Baricitinib

    October 2019 in “ JAAD Case Reports ”
    Brianna Olamiju, Adam Friedmann, Brett King
    Studysummary This article discusses the role of interleukin-15 and Janus kinase inhibitors in alopecia areata based on a murine model and reports no new experimental results.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jaadcasereports.org →
    Discuss this study in the Community →

    Research cited in this study 7

    1. Alopecia Areata: Overview and Insights from January 2018 Journal of The American Academy of Dermatology · 2017
    2. Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients Journal of The American Academy of Dermatology · 2016
    3. Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata JCI insight · 2016
    4. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016
    5. Health-Related Quality of Life Among Patients With Alopecia Areata: A Systematic Review Journal of The American Academy of Dermatology · 2016
    6. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib EBioMedicine · 2015
    7. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014

    Related research 1

    1. Twenty Nail Dystrophy with Alopecia Areata in an Atopic Child International journal of research in dermatology · 2019